Literature DB >> 1326319

Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma.

K S Oláh1, J A Dunn, H Gee.   

Abstract

OBJECTIVE: To determine the survival data for the various tumour types of uterine sarcoma and determine the influence of various prognostic factors on survival.
DESIGN: Retrospective analysis of all uterine sarcoma cases registered in the 15 year period 1967-1981.
SETTING: West Midlands Regional Cancer Registry, serving a catchment area of 2.6 million women.
SUBJECTS: 423 women registered as having a uterine sarcoma; 367 of these were associated with the two main histological types, leiomyosarcomas (LMS) and mixed mesodermal tumours (MMT). MAIN OUTCOME MEASURES: Duration of survival was taken as the primary endpoint.
RESULTS: The overall 5-year survival for uterine sarcomas in this series was 31%, with the major prognostic indicator being tumour stage. Survival for mixed mesodermal tumours is similar to other sarcomas despite a tendency towards less differentiation, wider dissemination and a greater age of the patient at diagnosis. Multivariate analysis shows that for cases with similar stage, age and grade, mixed mesodermal tumours have a better prognosis than leiomyosarcomas.
CONCLUSIONS: These results demonstrate the danger of considering each variable in isolation when the relation between variables can lead to spurious significance or lack of significance because of the imbalances in the numbers between groups of prognostic importance. This study underlines the need for an adequate inspection of the intra-abdominal contents at the time of hysterectomy for uterine fibroids.

Entities:  

Mesh:

Year:  1992        PMID: 1326319     DOI: 10.1111/j.1471-0528.1992.tb13827.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  16 in total

Review 1.  A review of treatment of uterine leiomyosarcomas.

Authors:  Nicholas Reed
Journal:  Curr Oncol Rep       Date:  2013-12       Impact factor: 5.075

Review 2.  Laboratory Assays in Evaluation of Lynch Syndrome in Patients with Endometrial Carcinoma.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2016-04-11

Review 3.  Role of the clinical pathology laboratory in the evaluation of endometrial carcinomas for Lynch syndrome.

Authors:  Bojana Djordjevic; Russell R Broaddus
Journal:  Semin Diagn Pathol       Date:  2014-04-02       Impact factor: 3.464

4.  The hormonal receptor status of uterine carcinosarcomas (mixed müllerian tumours): an immunohistochemical study.

Authors:  A C Ansink; P A Cross; P Scorer; A de Barros Lopes; J M Monaghan
Journal:  J Clin Pathol       Date:  1997-04       Impact factor: 3.411

Review 5.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant
Journal:  Cochrane Database Syst Rev       Date:  2011-01-19

6.  A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Linda R Duska; John A Blessing; Jacob Rotmensch; Robert S Mannel; Parviz Hanjani; Peter G Rose; Don S Dizon
Journal:  Gynecol Oncol       Date:  2014-08-01       Impact factor: 5.482

Review 7.  Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.

Authors:  Khadra Galaal; Esther van der Heijden; Keith Godfrey; Raj Naik; Ali Kucukmetin; Andrew Bryant; Nagindra Das; Alberto D Lopes
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Application of Immunohistochemistry and Molecular Diagnostics to Clinically Relevant Problems in Endometrial Cancer Bojana Djordjevic, Shannon Westin, Russell R. Broaddus.

Authors:  Bojana Djordjevic; Shannon Westin; Russell R Broaddus
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  How to deal with prognostic factors and radiotherapy results in uterine neoplasms with a sarcomatous component?

Authors:  Angeles Rovirosa; Carlos Ascaso; Jaume Ordi; Meritxell Arenas; Izaskun Valduvieco; José-Antonio Lejarcegui; Jaume Pahisa; Aureli Torne; Albert Biete
Journal:  Clin Transl Oncol       Date:  2009-10       Impact factor: 3.405

10.  Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.

Authors:  Tadao Takano; Hitoshi Niikura; Kiyoshi Ito; Satoru Nagase; Hiroki Utsunomiya; Takeo Otsuki; Masafumi Toyoshima; Hideki Tokunaga; Michiko Kaiho-Sakuma; Naomi Shiga; Tomoyuki Nagai; Sota Tanaka; Ai Otsuki; Hiroki Kurosawa; Shogo Shigeta; Keita Tsuji; Takuhiro Yamaguchi; Nobuo Yaegashi
Journal:  Int J Clin Oncol       Date:  2013-10-24       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.